Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence, Nature Reviews Clinical Oncology, vol.142, issue.2, pp.108-115, 2010. ,
DOI : 10.1038/nrclinonc.2009.217
Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia, The Lancet Oncology, vol.5, issue.4, pp.219-228, 2004. ,
DOI : 10.1016/S1470-2045(04)01425-1
Is Intraperitoneal Chemotherapy After Cytoreductive Surgery Efficient? Knowing Whether It Is or Not Appears Secondary!, Annals of Surgical Oncology, vol.12, issue.1, pp.5-6, 2012. ,
DOI : 10.1245/s10434-011-1897-7
Evolution of cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis: are there treatment alternatives?, The American Journal of Surgery, vol.201, issue.2, pp.157-159, 2011. ,
DOI : 10.1016/j.amjsurg.2010.04.010
Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study, European Journal of Surgical Oncology (EJSO), vol.36, issue.6, pp.589-593, 2010. ,
DOI : 10.1016/j.ejso.2010.04.005
URL : https://hal.archives-ouvertes.fr/hal-00599226
Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach, Expert Opinion on Pharmacotherapy, vol.6, issue.12, pp.1965-1977, 2009. ,
DOI : 10.1200/JCO.2003.04.187
Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, World Journal of Surgical Oncology, vol.7, issue.1, p.5, 2009. ,
DOI : 10.1186/1477-7819-7-5
Perioperative Management of Patients Undergoing Cytoreductive Surgery Combined with Heated Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: A Multi-Institutional Experience, Annals of Surgical Oncology, vol.54, issue.13, 2012. ,
DOI : 10.1245/s10434-012-2496-y
Radioimmunotherapy and colorectal cancer, British Journal of Surgery, vol.256, issue.3, pp.264-276, 2005. ,
DOI : 10.1002/bjs.4936
A Comparison Between Radioimmunotherapy and Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis of Colonic Origin in Rats, Annals of Surgical Oncology, vol.15, issue.11, pp.3274-3282, 2007. ,
DOI : 10.1245/s10434-007-9509-2
Brief Intraperitoneal Radioimmunotherapy of Small Peritoneal Carcinomatosis Using High Activities of Noninternalizing 125I-Labeled Monoclonal Antibodies, Journal of Nuclear Medicine, vol.51, issue.11, pp.1748-1755, 2010. ,
DOI : 10.2967/jnumed.110.080226
URL : https://hal.archives-ouvertes.fr/inserm-00531603
Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis, Journal of Nuclear Medicine, vol.50, issue.12, pp.2033-2041, 2009. ,
DOI : 10.2967/jnumed.109.066993
URL : https://hal.archives-ouvertes.fr/inserm-00442929
Phase III Trial of Intraperitoneal Therapy With Yttrium-90???Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission, Journal of Clinical Oncology, vol.24, issue.4, pp.571-578, 2006. ,
DOI : 10.1200/JCO.2005.02.5973
Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival, International Journal of Cancer, vol.19, issue.12, pp.2710-2714, 2007. ,
DOI : 10.1002/ijc.22663
Clinical radioimmunotherapy???the role of radiobiology, Nature Reviews Clinical Oncology, vol.33, issue.12, pp.720-734, 2011. ,
DOI : 10.1038/nrclinonc.2011.160
Cancer radioimmunotherapy, Immunotherapy, vol.3, issue.3, pp.349-370, 2011. ,
DOI : 10.2217/imt.10.114
URL : https://hal.archives-ouvertes.fr/hal-01258870
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view, Nuclear Medicine and Biology, vol.34, issue.7, pp.757-778, 2007. ,
DOI : 10.1016/j.nucmedbio.2007.04.001
Alphaemitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry, J Nucl Med, vol.40, pp.166-176, 1999. ,
Effective treatment of a murine model of adult T-cell leukemia using, 2006. ,
(alphaemitter )-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model, Cancer Res, vol.68, pp.213-3873, 2008. ,
Immunoliposomal Delivery of 213Bi for ??-Emitter Targeting of Metastatic Breast Cancer, Cancer Research, vol.70, issue.17, pp.6815-6823, 2010. ,
DOI : 10.1158/0008-5472.CAN-09-4548
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer, Cancer Res, vol.60, pp.6095-6100, 2000. ,
Alpha- versus Beta-Particle Radiopeptide Therapy in a Human Prostate Cancer Model (213Bi-DOTA-PESIN and 213Bi-AMBA versus177Lu-DOTA-PESIN), Cancer Research, vol.71, issue.3, pp.1009-1018, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-1186
Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted ?? Radioimmunoconjugates, Clinical Cancer Research, vol.15, issue.3, pp.865-875, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1203
Bismuth-213 radioimmunotherapy with C595 anti???MUC1 monoclonal antibody in an ovarian cancer ascites model, Cancer Biology & Therapy, vol.7, issue.1, pp.76-80, 2008. ,
DOI : 10.4161/cbt.7.1.5132
Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35, J Nucl Med, vol.46, pp.1907-1915, 2005. ,
Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model, Nuclear Medicine and Biology, vol.39, issue.1, pp.15-22, 2012. ,
DOI : 10.1016/j.nucmedbio.2011.07.003
Therapeutic Efficacy of Astatine-211???Labeled Trastuzumab on Radioresistant SKOV-3 Tumors in Nude Mice, International Journal of Radiation Oncology*Biology*Physics, vol.69, issue.2, pp.572-579, 2007. ,
DOI : 10.1016/j.ijrobp.2007.06.023
Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab???)2: therapeutic efficacy and myelotoxicity, Nuclear Medicine and Biology, vol.33, issue.8, pp.1065-1072, 2006. ,
DOI : 10.1016/j.nucmedbio.2006.07.009
Pb-Labeled Radioimmunoconjugate Targeting HER2, Cancer Biotherapy & Radiopharmaceuticals, vol.20, issue.5, pp.557-568, 2005. ,
DOI : 10.1089/cbr.2005.20.557
Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease, Clinical Cancer Research, vol.13, issue.6, pp.1926-1935, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2300
At-Labeled Humanized Monoclonal Antibody A33, Cancer Biotherapy & Radiopharmaceuticals, vol.22, issue.4, pp.480-487, 2007. ,
DOI : 10.1089/cbr.2007.349A
Intravesical ??-Radioimmunotherapy with 213Bi-Anti-EGFR-mAb Defeats Human Bladder Carcinoma in Xenografted Nude Mice, Journal of Nuclear Medicine, vol.50, issue.10, pp.1700-1708, 2009. ,
DOI : 10.2967/jnumed.109.065961
Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1, J Nucl Med, vol.38, pp.1944-1950, 1997. ,
Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice, Int J Oncol, vol.40, pp.1881-1888, 2012. ,
Multimodality Therapy: Potentiation of High Linear Energy Transfer Radiation with Paclitaxel for the Treatment of Disseminated Peritoneal Disease, Clinical Cancer Research, vol.14, issue.16, pp.5108-5115, 2008. ,
DOI : 10.1158/1078-0432.CCR-08-0256
Trastuzumab ??? Mechanism of Action and Use in Clinical Practice, New England Journal of Medicine, vol.357, issue.1, pp.39-51, 2007. ,
DOI : 10.1056/NEJMra043186
Improved in vivo stability and tumor targeting of bismuth-labeled antibody, Cancer Res, vol.50, pp.4221-4226, 1990. ,
Antigenic sites in carcinoembryonic antigen, Cancer Res, vol.49, pp.4852-4858, 1989. ,
Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines, European Journal of Immunology, vol.30, issue.4, pp.292-295, 1976. ,
DOI : 10.1002/eji.1830060411
Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha, Cancer Res, vol.56, pp.4758-4765, 1996. ,
Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts, Cancer Res, vol.58, pp.2825-2831, 1998. ,
Pb-Labeled Radioimmunoconjugate Targeting HER2, Cancer Biotherapy & Radiopharmaceuticals, vol.20, issue.5, pp.557-568, 2005. ,
DOI : 10.1089/cbr.2005.20.557
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb, Nuclear Medicine and Biology, vol.27, issue.1, pp.93-100, 2000. ,
DOI : 10.1016/S0969-8051(99)00086-4
Towards translation of 212Pb as a clinical therapeutic; getting the lead in!, Dalton Transactions, vol.91, issue.8, pp.6068-6076, 2011. ,
DOI : 10.1039/c0dt01387k
Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand???protein conjugates, Nuclear Medicine and Biology, vol.26, issue.8, pp.977-982, 1999. ,
DOI : 10.1016/S0969-8051(99)00054-2
Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice, International journal of oncology, vol.40, pp.1881-1888, 2012. ,
MIRD: Radionuclide Data and Decay Schemes, 2008. ,
Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. I. Presentation and Validation of a Microdosimetric Model, Radiation Research, vol.171, issue.6, pp.657-663, 2009. ,
DOI : 10.1667/RR1371.1
Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates, Current Radiopharmaceuticalse, vol.4, issue.4, pp.321-328, 2011. ,
DOI : 10.2174/1874471011104040321
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of ??-Particle Emitters for Targeted Radionuclide Therapy, Journal of Nuclear Medicine, vol.51, issue.2, pp.311-328, 2010. ,
DOI : 10.2967/jnumed.108.058651
Cell Membrane is a More Sensitive Target than Cytoplasm to Dense Ionization Produced by Auger Electrons, Radiation Research, vol.170, issue.2, pp.192-200, 2008. ,
DOI : 10.1667/RR1359.1
URL : https://hal.archives-ouvertes.fr/inserm-00311037
The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia, International Journal of Radiation Oncology*Biology*Physics, vol.34, issue.3, 1996. ,
DOI : 10.1016/0360-3016(95)02119-1
Targeted Alpha-Particle Immunotherapy for Acute Myeloid Leukemia, American Society of Clinical Oncology Educational Book, vol.34, pp.1233-1239, 2002. ,
DOI : 10.14694/EdBook_AM.2014.34.e126
Sequential Cytarabine and ??-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia, Clinical Cancer Research, vol.16, issue.21, pp.5303-5311, 2010. ,
DOI : 10.1158/1078-0432.CCR-10-0382
Intraperitoneal ??-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-1160, 2009. ,
DOI : 10.2967/jnumed.109.062604
Analysis of patient survival in a Phase I trial of systemic targeted ??-therapy for metastatic melanoma, Immunotherapy, vol.3, issue.9, pp.1041-1050, 2011. ,
DOI : 10.2217/imt.11.97
Clinical Experience with ??-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2008. ,
DOI : 10.2967/jnumed.107.046938